Kenvue shares rise despite Trump linking painkiller to autism risk
NeutralFinancial Markets
Kenvue's shares have seen an increase despite former President Trump's recent comments linking a painkiller to autism risk. This development is significant as it highlights the ongoing debate around the safety of pharmaceuticals and their potential side effects, which can impact public perception and market performance.
— Curated by the World Pulse Now AI Editorial System